Information Provided By:
Fly News Breaks for March 4, 2020
Mar 4, 2020 | 16:33 EDT
Citi analyst Joanne Wuensch initiated coverage of DexCom with a Buy rating and $330 price target. Dexcom is at the forefront of changing the standard of care of glucose monitoring with the commercialization of its continuous glucose monitor, Wuensch tells investors in a research note. Citi is "real believers in the CGM market, not only today but where it is going, with Dexcom at its lead," says the analyst.
News For DXCM From the Last 2 Days
There are no results for your query DXCM